logo-loader
viewCellmid Limited

Cellmid is a well funded life sciences company that see a path to profitability

Cellmid (ASX:CDY) Chief Executive and Managing Director Maria Halasz sat down with Christine Corrado from Proactive Investors New York to discuss their biotech company that now has products available in the United States.

Halasz telling Proactive they are about to spin out into 2 companies and she sees the company becoming profitable in 2020. 

Quick facts: Cellmid Limited

Price: 0.25 AUD

ASX:CDY
Market: ASX
Market Cap: $24.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Cellmid expanding products, portfolio and markets; and approaching profitablity

Cellmid Limited (ASX:CDY) CEO Maria Halasz speaks to Proactive Investors about the company's diversified and global operations, and recent cash raise. "We are fully funded are really ready to make this company a profitable entity. So the majority of the funding we really raised for our...

on 08/01/2018

2 min read